A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

NCT06394414 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: YL201

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.